SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Emery P. Early rheumatoid arthritis: therapeutic strategies. Scand J Rheumatol Suppl 1994; 100: 37.
  • 2
    Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalyses. Arthritis Rheum 1990; 33: 144961.
  • 3
    Fries JF. Effectiveness and toxicity considerations in outcome directed therapy in rheumatoid arthritis. J Rheumatol Suppl 1996; 44: 1026.
  • 4
    Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices. II. Second line drugs and prednisone. J Rheumatol 1992; 19: 188594.
  • 5
    Wolfe F, Hawley DJ, Cathey MA. Termination of slow acting antirheumatic therapy in rheumatoid arthritis: a 14-year prospective evaluation of 1017 consecutive starts. J Rheumatol 1990; 17: 9941002.
  • 6
    Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330: 136875.
  • 7
    Conaghan PG, Brooks P. Disease-modifying antirheumatic drugs, including methotrexate, gold, antimalarials, and D-penicillamine. Curr Opin Rheumatol 1995; 7: 16773.
  • 8
    Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis Rheum 1993; 36: 297306.
  • 9
    Van Ede AE, Laan RF, Blom HJ, de Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998; 27: 27792.
  • 10
    Wolfe F. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis. Clin Exp Rheumatol 1997; 15 Suppl 17: S7581.
  • 11
    Singh G, Fries JF. Can liver test abnormalities in patients with rheumatoid arthritis be predicted by clinical symptoms? J Rheumatol 1992; 19: 11589.
  • 12
    Brooks P. Current issues of methotrexate and cyclosporine. Curr Opin Rheumatol 1992; 4: 30913.
  • 13
    Camp AV. Hematologic toxicity from penicillamine in rheumatoid arthritis. J Rheumatol Suppl 1981; 7: 1645.
  • 14
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996; 39: 72331.
  • 15
    Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 31628.
  • 16
    Griffiths B, Emery P, Akehurst R. Economic evaluation in rheumatology: a necessity for clinical studies. Ann Rheum Dis 1995; 54: 8634.
  • 17
    Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ 1999; 318: 5936.
  • 18
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 19
    Pincus T, Callahan LF. The “side effects” of rheumatoid arthritis: joint destruction, disability and early mortality. Br J Rheumatol 1993; 32 Suppl 1: 2837.
  • 20
    Singh G, Fries JF, Williams CA, Zatarain E, Spitz P, Bloch DA. Toxicity profiles of disease modifying antirheumatic drugs in rheumatoid arthritis. J Rheumatol 1991; 18: 18894.
  • 21
    Austrian Society for Rheumatology. Consensus guidelines for monitoring DMARD treatment of RA. Accessed November 2001. URL: www.Rheuma2000.AT.
  • 22
    British Society for Rheumatology. Second line drug monitoring guidelines. Accessed April 2001. URL: www.rheumatology.org.uk.
  • 23
    Wijnands MJ, van Riel PL. Management of adverse effects of disease-modifying antirheumatic drugs. Drug Saf 1995; 13: 21927.
  • 24
    Deutsche Gesellschaft für Rheumatologie. Therapieüberwachungsrichtlinien für Ärzte. Accessed April 2001. URL: www.rheumanet.org.
  • 25
    Swedish Society for Rheumatology. Guidelines for monitoring of disease modifying antirheumatic drugs. Accessed November 2001. URL: www.svls.se.sektioner/srf.
  • 26
    Musterkatalog Labor.” Price list as obtained by the Austrian Chamber of Physicians.
  • 27
    Furst DE, Breedveld FC, Burmester GR, Crofford L, Emery P, Feldman M, et al. Access to disease modifying treatments for rheumatoid arthritis patients. Ann Rheum Dis 1999; 58 Suppl 1: 112930.
  • 28
    Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985; 312: 81822.
  • 29
    Beyeler C, Reichen J, Thomann SR, Lauterburg BH, Gerber NJ. Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: a longitudinal study. Br J Rheumatol 1997; 36: 33844.
  • 30
    Amos RS, Pullar T, Bax DE, Situnayake D, Capell HA, McCon-key B. Sulphasalazine for rheumatoid arthritis: toxicity in 774 patients monitored for one to 11 years. BMJ 1986; 293: 4203.
  • 31
    Bombardier C, Maetzel A. Pharmacoeconomic evaluation of new treatments: efficacy versus effectiveness studies? Ann Rheum Dis 1999; 58 Suppl 1: 1825.
  • 32
    Griner PF, Glaser RJ. Sounding boards: misuse of laboratory tests and diagnostic procedures. N Engl J Med 1982; 307: 13369.
  • 33
    Logan RL, Scott PJ. Uncertainty in clinical practice: implications for quality and costs of health care. Lancet 1996; 347: 5958.
  • 34
    Silman AJ, Symmons DP. Selection of study population in the development of rheumatic disease criteria: comment on the article by the American College of Rheumatology Diagnostic and Therapeutic Criteria Committee [letter]. Arthritis Rheum 1995; 38: 7223.
  • 35
    Martin AR, Wolf MA, Thibodeau LA, Dzau V, Braunwald E. A trial of two strategies to modify the test-ordering behavior of medical residents. N Engl J Med 1980; 303: 13306.
  • 36
    Katz JN, Wright EA, Lynch KD, Weinblatt ME. Evaluation of two interventions to reduce the ancillary costs of outpatient care for rheumatoid arthritis. Arthritis Rheum 1996; 39: 1778.
  • 37
    Fries JF, Ramey DR, Singh G. Suggested guidelines for monitoring liver toxicity in rheumatoid arthritis patients treated with methotrexate: comment on the article by Kremer et al [letter]. Arthritis Rheum 1994; 37: 182930.
  • 38
    Pisetsky D, Henderson A, Hudson N, Valez R. Remittive care for rheumatoid arthritis: challenges and problems for the VA. VA Practitioner 1984; 17: 469.